The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA approves Gazyva® (obinutuzumab) for patients with previously untreated advanced FL
On 16th November 2017, the U.S. Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) for the treatment of adults with previously untreated stage II bulky, III, or IV follicular lymphoma (FL), in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission.
This approval was based on the results of a multicenter, open-label, randomized phase 3 trial (GALLIUM) that was previously reported by Lymphoma Hub on December 12, 2016. The primary results of the study were presented at the American Society of Hematology (ASH) 2016 annual meeting that showed clinically significant improvement in the progression-free survival (PFS) of patients being treated with an obinutuzumab-based regimen compared to rituximab-based (PFS: rituximab = 73.3%, obinutuzumab = 80.0%, HR = 0.66 (p=0.0012)).
In an interview with Lymphoma Hub, Sonali Smith provided insight as to whether the GALLIUM study results would change current practice in first-line FL patients. She said that there will be "ongoing debate as to whether or not this should become the new standard of care." She also noted that since the improvement in PFS was modest and that there was no difference in overall survival, "we will continue to debate the value of these two monoclonal antibodies," and that "the statistically significant improvement will probably change practice for many physicians."
Full prescribing information can be found here.